HRP20110134T1 - Novi agonistički ligandi rar receptora i njihova upotreba u ljudskoj medicini i kozmetici - Google Patents
Novi agonistički ligandi rar receptora i njihova upotreba u ljudskoj medicini i kozmetici Download PDFInfo
- Publication number
- HRP20110134T1 HRP20110134T1 HR20110134T HRP20110134T HRP20110134T1 HR P20110134 T1 HRP20110134 T1 HR P20110134T1 HR 20110134 T HR20110134 T HR 20110134T HR P20110134 T HRP20110134 T HR P20110134T HR P20110134 T1 HRP20110134 T1 HR P20110134T1
- Authority
- HR
- Croatia
- Prior art keywords
- hydroxyprop
- ynyl
- hydrogen atom
- acne
- butyl
- Prior art date
Links
- 239000002537 cosmetic Substances 0.000 title claims abstract 6
- 239000003814 drug Substances 0.000 title claims abstract 3
- 239000003446 ligand Substances 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 15
- 239000000203 mixture Substances 0.000 claims abstract 3
- 238000000034 method Methods 0.000 claims abstract 2
- -1 alkyl radical Chemical group 0.000 claims 14
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 13
- 208000002874 Acne Vulgaris Diseases 0.000 claims 10
- 206010000496 acne Diseases 0.000 claims 10
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 claims 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- QUPDWYMUPZLYJZ-UHFFFAOYSA-N ethyl Chemical compound C[CH2] QUPDWYMUPZLYJZ-UHFFFAOYSA-N 0.000 claims 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 3
- 230000003612 virological effect Effects 0.000 claims 3
- 206010003645 Atopy Diseases 0.000 claims 2
- 206010003694 Atrophy Diseases 0.000 claims 2
- 208000012641 Pigmentation disease Diseases 0.000 claims 2
- 230000032683 aging Effects 0.000 claims 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 claims 2
- 230000037444 atrophy Effects 0.000 claims 2
- 208000035269 cancer or benign tumor Diseases 0.000 claims 2
- 230000024245 cell differentiation Effects 0.000 claims 2
- 230000004663 cell proliferation Effects 0.000 claims 2
- 229910052801 chlorine Inorganic materials 0.000 claims 2
- 125000001309 chloro group Chemical group Cl* 0.000 claims 2
- 230000002500 effect on skin Effects 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 230000002757 inflammatory effect Effects 0.000 claims 2
- 230000003780 keratinization Effects 0.000 claims 2
- 230000035755 proliferation Effects 0.000 claims 2
- 230000005855 radiation Effects 0.000 claims 2
- 208000017520 skin disease Diseases 0.000 claims 2
- 206010000501 Acne conglobata Diseases 0.000 claims 1
- 208000027932 Collagen disease Diseases 0.000 claims 1
- 208000002506 Darier Disease Diseases 0.000 claims 1
- 201000004624 Dermatitis Diseases 0.000 claims 1
- 206010013786 Dry skin Diseases 0.000 claims 1
- 206010020880 Hypertrophy Diseases 0.000 claims 1
- 206010023369 Keratosis follicular Diseases 0.000 claims 1
- 206010033554 Palmoplantar keratoderma Diseases 0.000 claims 1
- 206010049422 Precancerous skin lesion Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims 1
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims 1
- 206010040925 Skin striae Diseases 0.000 claims 1
- 208000031439 Striae Distensae Diseases 0.000 claims 1
- 208000002474 Tinea Diseases 0.000 claims 1
- 241000893966 Trichophyton verrucosum Species 0.000 claims 1
- 208000009621 actinic keratosis Diseases 0.000 claims 1
- 239000003513 alkali Substances 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 208000010668 atopic eczema Diseases 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229960001334 corticosteroids Drugs 0.000 claims 1
- 230000037336 dry skin Effects 0.000 claims 1
- 125000005843 halogen group Chemical group 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 206010021198 ichthyosis Diseases 0.000 claims 1
- 230000001900 immune effect Effects 0.000 claims 1
- 208000026278 immune system disease Diseases 0.000 claims 1
- 201000004607 keratosis follicularis Diseases 0.000 claims 1
- 208000002741 leukoplakia Diseases 0.000 claims 1
- 230000003211 malignant effect Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 150000007522 mineralic acids Chemical class 0.000 claims 1
- 210000004400 mucous membrane Anatomy 0.000 claims 1
- 230000003287 optical effect Effects 0.000 claims 1
- 150000007524 organic acids Chemical class 0.000 claims 1
- 235000005985 organic acids Nutrition 0.000 claims 1
- 201000008743 palmoplantar keratosis Diseases 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 230000019612 pigmentation Effects 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 201000004700 rosacea Diseases 0.000 claims 1
- 210000001732 sebaceous gland Anatomy 0.000 claims 1
- 230000009759 skin aging Effects 0.000 claims 1
- 230000009885 systemic effect Effects 0.000 claims 1
- 150000003751 zinc Chemical class 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/06—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with radicals, containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
- C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Dermatology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Hydrogenated Pyridines (AREA)
Abstract
Spojevi opće formule (I) niže: naznačeni time što:- R1 je atom vodika ili alkilni radikal koji sadrži 1 do 4 atoma ugljika,- R2 je alkilni radikal koji sadrži 1 do 4 atoma ugljika,- ili R1 i R2, zajedno s atomom dušika N na kojeg su vezani, mogu tvoriti heterocikl piperidinskog ili pirolidinskog tipa,- R3 je alkilni radikal koji sadrži 1 do 4 atoma ugljika,- R4 je vodik, alkilni radikal koji sadrži 1 do 4 atoma ugljika ili atom halogena,- R5 je atom vodika ili hidroksil,- R6 je atom vodika ili alkilni radikal koji sadrži 1 do 4 atoma ugljika, a također i njihove soli i optički izomeri. Patent sadrži još 16 patentnih zahtjeva.
Claims (17)
1. Spojevi opće formule (I) niže:
[image]
naznačeni time što:
– R1 je atom vodika ili alkilni radikal koji sadrži 1 do 4 atoma ugljika,
– R2 je alkilni radikal koji sadrži 1 do 4 atoma ugljika,
– ili R1 i R2, zajedno s atomom dušika N na kojeg su vezani, mogu tvoriti heterocikl piperidinskog ili pirolidinskog tipa,
– R3 je alkilni radikal koji sadrži 1 do 4 atoma ugljika,
– R4 je vodik, alkilni radikal koji sadrži 1 do 4 atoma ugljika ili atom halogena,
– R5 je atom vodika ili hidroksil,
– R6 je atom vodika ili alkilni radikal koji sadrži 1 do 4 atoma ugljika,
a također i njihove soli i optički izomeri.
2. Spojevi u skladu s patentnim zahtjevom 1, naznačeni time što imaju najmanje jednu od sljedećih karakteristika:
– R1 se bira između atoma vodika ili metilnog ili etilnog radikala,
– R2 se bira između metilnog, etilnog i 2-metilpropilnog radikala ili
– R1 i R2 tvore, zajedno s atomom dušika N na kojeg su vezani, heterocikl piperidinskog ili pirolidinskog tipa,
– R3 se bira između i-propilnog i t-butilnog radikala,
– R4 se bira između atoma vodika, metilnog ili etilnog radikala, i-propilnog radikala i atoma klora,
– R5 je atom vodika ili hidroksil,
– R6 je atom vodika ili alkilni radikal koji sadrži 1 do 4 atoma ugljika.
3. Spojevi u skladu s patentnim zahtjevom 1 ili 2, naznačeni time što imaju sve od sljedećih karakteristika:
– R1 se bira između atoma vodika ili metilnog ili etilnog radikala,
– R2 se bira između metilnog, etilnog i 2-metilpropilnog radikala ili
– R1 i R2 tvore, zajedno s atomom dušika N na kojeg su vezani, heterocikl piperidinskog ili pirolidinskog tipa,
– R3 se bira između i-propilnog i t-butilnog radikala,
– R4 se bira između atoma vodika, metilnog ili etilnog radikala, i-propilnog radikala i atoma klora,
– R5 je atom vodika ili hidroksil,
– R6 je atom vodika ili alkilni radikal koji sadrži 1 do 4 atoma ugljika.
4. Spojevi u skladu s patentnim zahtjevom 1, naznačeni time što su u obliku soli, koju se bira između soli alkalnog ili zemnoalkalnog metala, cinkovih soli i soli organskih amina.
5. Spojevi u skladu s patentnim zahtjevom 1, naznačeni time što R1 je atom vodika ili alkilni radikal koji sadrži 1 do 4 atoma ugljika, a R2 je alkilni radikal koji sadrži 1 do 4 atoma ugljika, te time što su u obliku soli, koju se bira između soli anorganskih i soli organskih kiselina.
6. Spoj u skladu s patentnim zahtjevom 1, naznačeni time što ga se bira između:
1/– 4-[(tert-butildietilaminofenil)hidroksiprop-1-inil]benzojeve kiseline
2/– 4-{[tert-butil(etilizobutilamino)fenil]hidroksiprop-1-inil}benzojeve kiseline
3/– 4-[3-(3-tert-butil-4-dimetilaminofenil)-3-hidroksiprop-1-inil]benzojeve kiseline
4/– 4-[3-(3-tert-butil-4-pirolidin-1-ilfenil)-3-hidroksiprop-1-inil]benzojeve kiseline
5/– 4-[3-(3-tert-butil-4-piperidin-1-ilfenil)-3-hidroksiprop-1-inil]benzojeve kiseline
6/– 4-[3-(3-tert-butil-4-dietilaminofenil)-3-hidroksiprop-1-inil]-2-hidroksibenzojeve kiseline
7/– 4-[3-(3-tert-butil-5-klor-4-dimetilaminofenil)-3-hidroksiprop-1-inil]benzojeve kiseline
8/– 4-[3-(3-tert-butil-5-klor-4-dimetilaminofenil)-3-hidroksiprop-1-inil]-2-hidroksibenzojeve kiseline
9/– 4-[3-(4-dimetilamino-3,5-diizopropilfenil)-3-hidroksiprop-1-inil]benzojeve kiseline
10/– 4-[3-(4-dimetilamino-3,5-diizopropilfenil)-3-hidroksiprop-1-inil]-2-hidroksibenzojeve kiseline
11/– 4-[3-(4-dietilamino-3-izopropilfenil)-3-hidroksiprop-1-inil]benzojeve kiseline
12/– (-)-4-[3-(3-tert-butil-4-dietilaminofenil)-3-hidroksiprop-1-inil]benzojeve kiseline
13/– (+)-4-[3-(3-tert-butil-4-dietilaminofenil)-3-hidroksiprop-1-inil]benzojeve kiseline.
7. Spojevi u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačeni time što su namijenjeni upotrebi kao medikamenti.
8. Upotreba najmanje jednog spoja u skladu s bilo kojim od patentnih zahtjeva 1 do 6, naznačena time što je navedeni najmanje jedan spoj namijenjen proizvodnji pripravka namijenjenog upotrebi u liječenju:
– dermatoloških stanja povezanih s poremećajem keratinizacije povezanim sa staničnom diferencijacijom i proliferacijom;
– ihtioze, ihtioziformnih stanja, Darierove bolesti, palmoplantarne keratoderme, leukoplakije i leukoplakiformnih stanja, te lišaja na koži ili sluznicama;
– dermatoloških stanja s upalnom imunoalergijskom komponentom, uz ili bez poremećaja stanične proliferacije;
– poremećaje kože, uzrokovanih izlaganjem UV zračenju, fotoindukcijom ili kronološkim starenjem kože, ili pigmentacije i aktinične keratoze;
– patoloških stanja povezanih s kronološkim ili aktiničnim starenjem kože;
– dermalnih ili epidermalnih proliferacija, bilo dobroćudnih ili zloćudnih, virusnog ili nevirusnog podrijetla;
– proliferacija koje može inducirati ultraljubičasto zračenje;
– prekanceroznih lezija kože;
– imunosnih dermatoza;
– buloznih imunosnih bolesti;
– kolagenskih bolesti;
– dermatoloških stanja s imunološkom komponentom;
– oftalmoloških poremećaja;
– stigma epidermalne i/ili dermalne atrofije induciranih lokalnim ili sistemnim kortikosteroidima, ili bilo kojih drugih oblika kutane atrofije;
– kutanih stanja virusnog podrijetla;
– poremećaja funkcija lojnih žlijezda;
– poremećaja cikatrizacije ili strija; ili
– poremećaja pigmentacije.
9. Upotreba u skladu s patentnim zahtjevom 8, naznačena time što dermatološka stanja povezana s poremećajem keratinizacije povezanim sa staničnom diferencijacijom i proliferacijom se bira između običnih akni, komedonalnih akni, polimorfnih akni, akni rozacea, nodulocističnih akni, acne conglobata, staračkih akni, sekundarnih akni, poput solarnih akni, medikamentoznih akni ili profesionalnih akni.
10. Upotreba spojeva u skladu s patentnim zahtjevom 8, naznačena time što dermatološka stanja s upalnom imunoalergijskom komponentom, uz ili bez poremećaja stanične proliferacije, se bira između psorijaze, psorijatičnog artritisa, kutane atopije, poput ekzema, ili respiratorne atopije i hipertrofije desni.
11. Farmaceutski pripravak, naznačen time što sadrži, u fiziološki prihvatljivom mediju, najmanje jedan spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6.
12. Pripravak u skladu s patentnim zahtjevom 11, naznačeni time što koncentracija spojeva formule (I) je između 0,001 % i 10 %, težinski, po mogućnosti između 0,01 % i 1 %, težinski, u odnosu na težinu pripravka.
13. Kozmetički pripravak, naznačen time što sadrži, u fiziološki prihvatljivom mediju, najmanje jedan spoj formule (I) u skladu s bilo kojim od patentnih zahtjeva 1 do 6.
14. Pripravak u skladu s patentnim zahtjevom 13, naznačen time što koncentracija spojeva formule (I) je između 0,001 % i 3 %, težinski, u odnosu na the total težina pripravka.
15. Neterapijska upotreba kozmetičkog pripravka u skladu s bilo kojim od patentnih zahtjeva 13 i 14, naznačena time što je navedeni pripravak namijenjen sprječavanju i/ili liječenju znakova starenja kože i/ili suhe kože.
16. Neterapijska upotreba kozmetičkog pripravka u skladu s bilo kojim od patentnih zahtjeva 13 i 14, naznačena time što je navedeni pripravak namijenjen higijeni tijela ili kose.
17. Kozmetički postupak, namijenjen poboljšavanju izgleda kože, naznačeni time što pripravak u skladu s bilo kojim od patentnih zahtjeva 13 i 14 se primijenjuje na kožu.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0755019A FR2915993B1 (fr) | 2007-05-11 | 2007-05-11 | Nouveaux ligands agonistes des recepteurs pars, utilisation en medecine humaine ainsi qu'en cosmetique. |
| PCT/FR2008/050747 WO2008152260A2 (fr) | 2007-05-11 | 2008-04-24 | Nouveaux ligands agonistes des recepteurs rars, utilisation en medecine humaine ainsi qu'en cosmetique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110134T1 true HRP20110134T1 (hr) | 2011-04-30 |
Family
ID=38792049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110134T HRP20110134T1 (hr) | 2007-05-11 | 2011-02-24 | Novi agonistički ligandi rar receptora i njihova upotreba u ljudskoj medicini i kozmetici |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US8163952B2 (hr) |
| EP (1) | EP2146951B1 (hr) |
| AT (1) | ATE490233T1 (hr) |
| CA (1) | CA2686223A1 (hr) |
| CY (1) | CY1111361T1 (hr) |
| DE (1) | DE602008003788D1 (hr) |
| DK (1) | DK2146951T3 (hr) |
| ES (1) | ES2357193T3 (hr) |
| FR (1) | FR2915993B1 (hr) |
| HR (1) | HRP20110134T1 (hr) |
| PL (1) | PL2146951T3 (hr) |
| PT (1) | PT2146951E (hr) |
| SI (1) | SI2146951T1 (hr) |
| WO (1) | WO2008152260A2 (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3650448A4 (en) | 2017-07-06 | 2021-03-31 | Jiangsu Hengrui Medicine Co., Ltd. | INDOLE-FORMAMIDE, PROCESS OF PREPARATION AND USE IN MEDICINE |
| CA3075324A1 (en) | 2017-09-12 | 2019-03-21 | Jiangsu Hengrui Medicine Co., Ltd. | Deuterium atom-substituted indole formamide derivative, preparation method therefor, and medical applications thereof |
| CN109776302A (zh) * | 2017-11-13 | 2019-05-21 | 中国科学院化学研究所 | 一种由木质素为甲基源制备重要化学品的方法 |
| US11135236B2 (en) | 2018-04-10 | 2021-10-05 | Northwestern University | Retinoic acid receptor gamma agonists to attenuate anthracycline-induced cardiotoxicity |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2840300B1 (fr) * | 2002-06-04 | 2004-07-16 | Galderma Res & Dev | NOUVEAUX LIGANDS INHIBITEURS DES RECEPTEURS RARs, LEUR PROCEDE DE PREPARATION ET LEUR UTILISATION EN MEDECINE HUMAINE AINSI QU'EN COSMETIQUE |
| BR0309786A (pt) | 2002-06-04 | 2005-03-22 | Galderma Res & Dev | Compostos, seu uso, composição farmacêutica, composição cosmética e uso cosmético de uma composição |
| CN1659132A (zh) * | 2002-06-04 | 2005-08-24 | 盖尔德马研究及发展公司 | 作为rar受体抑制剂的新型配体,制备它们的方法及其在人药物和化妆品方面的用途 |
-
2007
- 2007-05-11 FR FR0755019A patent/FR2915993B1/fr not_active Expired - Fee Related
-
2008
- 2008-04-24 AT AT08805701T patent/ATE490233T1/de active
- 2008-04-24 ES ES08805701T patent/ES2357193T3/es active Active
- 2008-04-24 PL PL08805701T patent/PL2146951T3/pl unknown
- 2008-04-24 SI SI200830114T patent/SI2146951T1/sl unknown
- 2008-04-24 DE DE602008003788T patent/DE602008003788D1/de active Active
- 2008-04-24 WO PCT/FR2008/050747 patent/WO2008152260A2/fr active Application Filing
- 2008-04-24 EP EP08805701A patent/EP2146951B1/fr active Active
- 2008-04-24 CA CA002686223A patent/CA2686223A1/fr not_active Abandoned
- 2008-04-24 US US12/599,624 patent/US8163952B2/en not_active Expired - Fee Related
- 2008-04-24 PT PT08805701T patent/PT2146951E/pt unknown
- 2008-04-24 DK DK08805701.3T patent/DK2146951T3/da active
-
2011
- 2011-02-11 CY CY20111100168T patent/CY1111361T1/el unknown
- 2011-02-24 HR HR20110134T patent/HRP20110134T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2146951A2 (fr) | 2010-01-27 |
| PL2146951T3 (pl) | 2011-05-31 |
| US20100261754A1 (en) | 2010-10-14 |
| SI2146951T1 (sl) | 2011-02-28 |
| PT2146951E (pt) | 2011-02-22 |
| ATE490233T1 (de) | 2010-12-15 |
| EP2146951B1 (fr) | 2010-12-01 |
| CA2686223A1 (fr) | 2008-12-18 |
| CY1111361T1 (el) | 2015-08-05 |
| US8163952B2 (en) | 2012-04-24 |
| WO2008152260A2 (fr) | 2008-12-18 |
| FR2915993B1 (fr) | 2009-07-03 |
| ES2357193T3 (es) | 2011-04-19 |
| DK2146951T3 (da) | 2011-02-28 |
| WO2008152260A3 (fr) | 2009-02-12 |
| FR2915993A1 (fr) | 2008-11-14 |
| DE602008003788D1 (de) | 2011-01-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2753300B2 (ja) | 芳香族エステル及びチオエステル | |
| JP2653992B2 (ja) | ポリエン化合物およびそれを含有する医薬品組成物および化粧品組成物 | |
| JP6239543B2 (ja) | シワ改善剤 | |
| RU98109793A (ru) | Триароматические соединения, содержащие их композиции и их применение | |
| NZ286444A (en) | Use of 7-Adamantyl-naphth-2-yl(hetero)aryl carboxylic acids and derivatives thereof (retinoid analogues) as pharmaceutical agents | |
| WO2007148832A1 (ja) | 亜鉛を有効成分として含有する美白剤 | |
| JPH01268632A (ja) | 組成物 | |
| RU2004122394A (ru) | Бифенилметилтиазолидиндионы и аналоги и их применение в качестве активаторов ppar-gama | |
| HRP20110134T1 (hr) | Novi agonistički ligandi rar receptora i njihova upotreba u ljudskoj medicini i kozmetici | |
| EA001216B1 (ru) | Бициклические ароматические соединения, фармацевтическая и косметическая композиции на их основе и применение косметической композиции | |
| NZ270914A (en) | Adamantyl-substituted biaromatic acetylene derivatives; pharmaceutical and cosmetic use | |
| JP2015528499A (ja) | イデベノンとｎ−アセチル−ｓ−ファルネシル−ｌ−システインとエルゴチオネインとを含む調合物及びその使用法 | |
| DE69804205T2 (de) | Bi-aromatische verbindungen und diese enthaltende pharmazeutische und kosmetische zusammenstellungen | |
| JP2000514781A (ja) | 複素環ビアリール化合物、それを含有する医薬組成物および化粧品組成物ならびにその使用 | |
| US5935585A (en) | Biaromatic amido compounds and pharmaceutical/cosmetic compositions comprised thereof | |
| CA2514558A1 (en) | Invert emulsion type composition containing at least one active agent sensitive to the presence of water, and its uses in cosmetics and in dermatology | |
| CA2505286A1 (en) | Novel ligands that are antagonists of rar receptors, process for preparing them and use thereof in human medicine and in cosmetics | |
| JPH10101543A (ja) | チロシナーゼ活性阻害剤及び化粧料 | |
| JP2011012055A (ja) | ビタミン類を含有する皮膚外用組成物 | |
| DE69806465T2 (de) | Eine heteroethynylen-brücke enthaltende bi-aromatische verbindungen und diese enthaltende pharmazeutische und kosmetische zusammensetzungen | |
| CA2578019A1 (en) | Cosmetic compositions | |
| RU2004138294A (ru) | Новые лиганды, являющиеся ингибититорами рецепторов rar, способ их получения и их применение для лечения человека и в лечебной косметике | |
| CA2646775C (en) | Cosmetic and pharmaceutical compositions | |
| ES2366627T3 (es) | Nuevos ligandos activadores de los receptores rar y utilización en medicina humana, así como en cosmética. | |
| CA2484450A1 (en) | Ligands that are inhibitors of the rar receptors |